基于队列内试验(TwiCs)设计的随机试验的特征、知情同意模式与挑战:一项范围综述
该范围综述系统检索截至2022年12月的文献,共识别2005至2022年间14个国家开展的46项TwiCs。TwiCs多为研究者发起、公共资助、招募门诊患者,最常见于肿瘤学(24%)、感染性疾病(17%)和精神卫生(15%)。知情同意模式有三种,干预非采纳率中位数为25%,仅42%的试验调整了样本量,45%计划调整效应估计,知情同意程序变异大且干预非采纳可能较大,需进一步研究。
要点
- TwiCs设计在全球呈分散分布,仅少数研究组开展,数量仍较少。
- 仅42%的TwiCs调整样本量以应对干预非采纳,中位非采纳率为25%。
- 知情同意模式存在三种变异,41%的TwiCs未提及随机化同意。
核心结论
- 现有TwiCs全球分散于少数研究组,覆盖广泛医学领域和干预措施,尽管有潜在优势,数量仍少。
- 知情同意程序变异大及干预非采纳可能性大,需进一步研究以指导TwiCs的规划、实施和分析。
研究设计与样本
- 范围综述,系统检索Medline、Embase、Cochrane、试验注册库及引文追踪至2022年12月。
- TwiCs定义为嵌入队列的随机试验,干预组随机后知情同意,常规照护对照组无特定随机后知情同意。
- 共识别46项TwiCs,于2005至2022年间在14个不同国家由少数研究组开展。
主要发现
- 最常见医学领域为肿瘤学(11/46;24%)、感染性疾病(8/46;17%)和精神卫生(7/46;15%)。
- 典型TwiCs为研究者发起(46/46;100%)、公共资助(36/46;78%)、招募门诊患者(27/46;59%)。
- 排除8项试点试验后,仅16/38(42%)TwiCs调整计算样本量以应对干预非采纳,预期实验组中位非采纳率25%(四分位距10%-32%)。
- 17项TwiCs(45%)计划分析调整效应估计以应对非采纳。
- 知情同意模式:队列参与、随机化和干预三种独立同意(17/46;37%);队列参与和随机化合并同意及独立干预同意(10/46;22%);仅队列参与和干预同意(未提及随机化同意;19/46;41%)。
临床怎么用
- 作者认为,知情同意程序变异大及干预非采纳可能性大,需进一步研究以指导TwiCs的规划、实施和分析。
局限性
- 知情同意程序变异大及干预非采纳可能性大,需进一步研究以指导TwiCs的规划、实施和分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Trials within Cohorts (TwiCs) is a pragmatic design approach that may overcome frequent challenges of traditional randomized trials such as slow recruitment, burdensome consent procedures, or limited external validity. This scoping review aims to identify all randomized controlled trials using the TwiCs design and to summarize their design characteristics, ways to obtain informed consent, output, reported challenges and mitigation strategies. STUDY DESIGN AND SETTING: Systematic search of Medline, Embase, Cochrane, trial registries and citation tracking up to December 2022. TwiCs were defined as randomized trials embedded in a cohort with postrandomization consent for the intervention group and no specific postrandomization consent for the usual care control group. Information from identified TwiCs was extracted in duplicate from protocols, publications, and registry entries. We analyzed the information descriptively and qualitatively to highlight methodological challenges and solutions related to nonuptake of interventions and informed consent procedure. RESULTS: We identified a total of 46 TwiCs conducted between 2005 and 2022 in 14 different countries by a handful of research groups. The most common medical fields were oncology (11/46; 24%), infectious diseases (8/46; 17%), and mental health (7/46; 15%). A typical TwiCs was investigator-initiated (46/46; 100%), publicly funded (36/46; 78%), and recruited outpatients (27/46; 59%). Excluding eight pilot trials, only 16/38 (42%) TwiCs adjusted their calculated sample size for nonuptake of the intervention, anticipating a median nonuptake of 25% (interquartile range 10%-32%) in the experimental arm. Seventeen TwiCs (45%) planned analyses to adjust effect estimates for nonuptake. Regarding informed consent, we observed three patterns: 1) three separate consents for cohort participation, randomization, and intervention (17/46; 37%); 2) combined consent for cohort participation and randomization and a separate intervention consent (10/46; 22%); and 3) consent only for cohort participation and intervention (randomization consent not mentioned; 19/46; 41%). CONCLUSION: Existing TwiCs are globally scattered across a few research groups covering a wide range of medical fields and interventions. Despite the potential advantages, the number of TwiCs remains small. The variability in consent procedures and the possibility of substantial nonuptake of the intervention warrants further research to guide the planning, implementation, and analysis of TwiCs.
引用
- Amstutz A, Schönenberger CM, Speich B, et al. Characteristics, consent patterns, and challenges of randomized trials using the Trials within Cohorts (TwiCs) design - A scoping review. J Clin Epidemiol. 2024. PMID: 39032590. doi:10.1016/j.jclinepi.2024.111469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。